Health Care · Biological Products, (No Diagnostic Substances)

AUTL Autolus Therapeutics plc SEC Filings & Insider Trading Activity 2026

company
CIK 173046330 filings

AUTL at a glance

Autolus Therapeutics plc (AUTL, SEC CIK 1730463) filed its latest 20-F annual report on March 7, 2023 and Form 4 insider filings as recently as September 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 15 institutional investment managers tracked by SignalX reported holding Autolus Therapeutics plc (AUTL) shares worth $65.4 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Piccina Cintia on September 2, 2026 of 6,713 shares at $2.34 per share.
  • In the last 90 days, AUTL insiders reported 0 open-market purchases ($0) and 1 open-market sale ($16K) on Form 4, a net sale of $16K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 1 sell
Net −$16K
13F holders
15 funds
$65.4M · −1 vs prior quarter
Latest 8-K
Nov 10, 2026
Item 2.02 · Item 7.01

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 10, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results and corporate update announced for quarter ended September 30, 2026
  • Press release furnished as Exhibit 99.1, containing the substantive financial and operational details

Item 7.01: Regulation FD Disclosure

  • Updated corporate presentation accompanies the November 10, 2026 conference call on quarter ended September 30, 2026 results
  • Exhibit 99.2 likely contains management’s latest business, pipeline and financial messaging for investor review

Item EX-99.1: Item EX-99.1

  • Q3 AUCATZYL revenue $41.2M, up 95% year over year, validating accelerating demand across treatment centers
  • 2026 revenue outlook raised to at least the upper end of $150M, signaling stronger commercial execution

Item EX-99.2: Item EX-99.2

  • Q3 2026 net product revenue $41.2M, up 95% versus Q3 2025; 9M revenue $113.1M, up 122%
  • 90 U.S. authorized treatment centers, exceeding the 2026 goal of more than 80
Filed Aug 11, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Quarterly results for period ended June 30, 2026, accompanied by a corporate update
  • Exhibit 99.1 contains the financial figures and management commentary investors need to assess performance

Item 7.01: Regulation FD Disclosure

  • Updated corporate presentation supports Autolus’s August 11, 2026 conference call on results for quarter ended June 30, 2026
  • Investors should review Exhibit 99.2 for management’s latest corporate and operating update

Item EX-99.2: Item EX-99.2

  • Q2 2026 AUCATZYL net product revenue $45.7M, up 119% year over year
  • FY 2026 net product revenue guidance raised to $140M-$150M from $120M-$135M

Item EX-99.1: Item EX-99.1

  • Q2 product revenue $45.7M, up 119% year-over-year and from $26.2M in Q1, confirming accelerating AUCATZYL commercial adoption
  • FY 2026 AUCATZYL revenue guidance raised to $140M-$150M from $120M-$135M, improving near-term growth visibility
Filed Aug 3, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • $75.0M drawn July 30, 2026 under senior secured facility, with up to $175.0M additional availability
  • Debt matures July 30, 2031, with monthly interest at 6.75%-7.25% plus greater of one-month SOFR or 3.50%

Item 2.03: Creation of a Direct Financial Obligation

  • Item 2.03 links to the Perceptive Senior Secured Notes Facility described under Item 1.01
  • New senior secured debt creates a direct financial obligation and may increase leverage

Item 3.02: Unregistered Sales of Equity Securities

  • Perceptive Warrants terms under Item 1.01 govern this unregistered equity issuance
  • Potential dilution and ownership impact depend on warrant shares and exercise terms disclosed in the incorporated section

AI summaries of AUTL 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for AUTL

Don't miss the next AUTL filing

  • Alerts as it files. A push when AUTL files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut AUTL, by share count.
  • Ask anything. An AI agent that reads every AUTL filing and answers with sources.

AUTL alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Piccina CintiaSellSep 2, 2026$2.34
Piccina CintiaMSep 1, 2026$2.35
Piccina CintiaMSep 1, 2026-
BONNEY MICHAEL WAJun 29, 2026-
YOUNG WILLIAM DAJun 29, 2026-
Azelby RobertAJun 29, 2026-
YOUNG WILLIAM DAJun 29, 2026-
Leiderman ElisabethAJun 29, 2026-

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate AUTL share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
AUTL shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202615$65.4M
Q2 202616$49.6M
Q1 202615$41.8M
Q4 202513$67.4M
Q3 202515$68.6M
Q2 202518$91.5M
Q1 202516$58.8M
Q4 202413$100.1M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 121 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

AUTL filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 20-F, 6-K

FormFiling dateAnalysisSEC
8-KNov 10, 2026Analysis-
4Sep 3, 2026--
8-KAug 11, 2026Analysis-
8-KAug 3, 2026Analysis-
8-KAug 3, 2026Analysis-
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
4Jul 1, 2026--
8-KJun 29, 2026Analysis-
8-KJun 9, 2026-
8-KMay 14, 2026-
8-KApr 29, 2026--
8-KApr 16, 2026--
8-KApr 8, 2026--
8-KMar 27, 2026--
8-KJan 26, 2026-
8-KJan 12, 2026-
8-KDec 2, 2025-
20-FMar 7, 2023-

Related Health Care companies

All Health Care →

AUTL SEC filings: frequently asked questions

Are AUTL insiders buying or selling?

In the last 90 days, Autolus Therapeutics plc (AUTL) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $15,682 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold AUTL stock?

As of September 30, 2026, the largest Autolus Therapeutics plc (AUTL) holders among the 13F filers tracked by SignalX were Blackstone Group ($39.7 million), Renaissance Technologies LLC ($4.8 million), Millennium Management ($4.2 million), Morgan Stanley ($4.1 million), Citadel Advisors LLC ($3.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did AUTL report in its latest 8-K?

Autolus Therapeutics plc (AUTL) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Q3 2026 financial results and corporate update announced for quarter ended September 30, 2026.

What are the latest AUTL SEC filings?

Autolus Therapeutics plc (AUTL) filed its latest 20-F annual report on March 7, 2023 and a Form 4 insider filing on September 3, 2026.

What is AUTL's SEC CIK number?

Autolus Therapeutics plc (AUTL)'s SEC Central Index Key (CIK) is 1730463. EDGAR lists every AUTL filing under that number.

Ask anything about AUTL

The research agent reads AUTL's filings, financials, insider trades and 13F holders, then answers with sources.